AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 282 min read$BSX

Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem?

Wells Fargo estimates Boston Scientific's (BSX) August cyber incident will reduce Q3 sales by $300M and EPS by $0.13, but long-term growth forecasts remain unchanged. The company expects to recover some lost revenue, though the full impact is uncertain. Boston Scientific plans to update its 2026 outlook on October 28.

Original reporting
insidermonkey.com
Published Sep 28, 2026, 6:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 7:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Could Boston Scientific’s $300 Million Cyber Hit Be Mostly a 2026 Problem? — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$BSXBearishMed
01

Why it matters

The estimate drives a near‑term earnings downgrade, though long‑term growth outlook remains unchanged.

02

Market read

The news introduces a fresh earnings‑impact estimate that could affect BSX pricing ahead of its Q3 results.

03

What to watch

Potential insurance recoveries or cost‑saving measures were not quantified in the estimate.

Relevance 7/10Novelty 7/10Timing: pre‑earnings, before Q3 results on Oct 28

Background

Boston Scientific disclosed an August cyber‑attack that halted manufacturing for eight days, prompting an analyst estimate of a $300 M Q3 sales hit.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Wells Fargo estimates a $300 million sales hit and $0.13 EPS reduction for Q3 2026 due to the August cyber‑incident.

Expected impact

likely pressure as the market prices in the earnings shortfall

Evidence & confidence

Analyst downgrade and price‑target cut reflect immediate earnings impact; no change to long‑term growth suggests the hit is confined to near‑term results.

Market effects

Sector

Healthcare device sector may see broader risk‑off sentiment as cyber‑risk exposure is highlighted.

Regional

U.S. markets could see modest pullback in med‑tech stocks.

Global

Limited to investors tracking Boston Scientific and related med‑device peers.

Counterpoint

What could challenge this read

If the company recovers the backlog faster than expected, the impact could be muted and the stock may rebound.

Key entities

  • company
    Boston Scientific Corporation

    Medical device maker impacted by cyber‑incident.

  • analyst_firm
    Wells Fargo

    Provided the $300 M impact estimate and lowered price target.

Read at source← All news

Related articles

SEP 28
$BSXMed

Why Oppenheimer Cut Boston Scientific’s Price Target by $20 Despite Keeping its Outperform Rating

Oppenheimer cut Boston Scientific's (BSX) price target to $65 from $85 due to a cybersecurity disruption and competitive pressures, but maintained an Outperform rating. The firm reduced fiscal 2026 and 2027 estimates, citing the impact of an eight-day cyberattack and competition in LAAC and EP markets. Boston Scientific reported $5.44 billion in Q2 revenue, up 7.5% YoY, but expects the cyberattack to materially impact Q3 and full-year 2026 results.

insidermonkey.com2 min
SEP 28
$BSXMedAI 8/10

Hydrogel Spacer Receives FDA 510(k) Clearance for Prostate Cancer Radiotherapy

The FDA cleared Boston Scientific's SpaceOAR Flex System, a hydrogel spacer for prostate cancer radiotherapy, via the 510(k) pathway. The clearance was based on the HYDROSPACE trial, which evaluates the device's safety and effectiveness in reducing radiation dose to the rectum. The device is intended for patients with low- to intermediate-risk prostate cancer undergoing external beam radiotherapy.

cancernetwork.com2 min
SEP 23
$BSXLow

Boston Scientific Corporation Announces Retirement of Arthur C. Butcher from Executive Vice President and Group President, Medsurg and Asia Pacific, Effective January 1, 2027

Boston Scientific Corporation announced that Arthur C. Butcher will retire as Executive Vice President and Group President, MedSurg and Asia Pacific, effective January 1, 2027. He will serve as a senior advisor until February 26, 2027. The company specializes in medical equipment and materials, with significant sales in cardiovascular, endodontic surgery, and neuromodulation products.

marketscreener.com1 min
SEP 23
$BSXLow

Boston Scientific MedSurg, Asia Pacific leader to retire

Boston Scientific (BSX) announced EVP Arthur Butcher will retire at year-end 2026, after 30 years with the company. Butcher, who oversees Asia-Pacific, China, and key business units, will stay as a senior advisor until February 2027. He joined in 1996 and held various leadership roles.

massdevice.com2 min
SEP 21
$BSXMed

BSX Maintained by Oppenheimer -- Price Target Lowered to $65

Oppenheimer maintained its 'Outperform' rating for Boston Scientific (BSX) but lowered its price target from $85 to $65. BSX is trading at $43.17, which is 59.8% undervalued according to its GF Value™ of $107.30. The company has a GF Score™ of 80/100, indicating strong overall performance but lower rankings in momentum and valuation.

gurufocus.com2 min